Celularity Inc. surged as stocks have been trading up by 13.58 percent following highly positive sentiment around its latest developments.
Click Here for a Millionaire's POV on Trading CELU
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- CELU has pushed off recent lows, with the stock closing near $0.88 after testing above $0.97, signaling aggressive day trading interest.
- Recent CELU intraday action shows a spike from $0.92 to $1.40 at the open, then a sharp fade, highlighting heavy volatility and fast momentum shifts.
- Celularity Inc. reports negative equity and deeply negative margins, putting balance-sheet strength front and center for CELU traders.
- Despite steep losses, CELU generated about $26.6M in revenue over the last year, giving traders a real operating business to track, not just a shell.
- Liquidity ratios for Celularity Inc. remain tight, forcing CELU traders to factor potential dilution or new funding into any longer-term thesis.
Live Update At 09:17:55 EDT: On Thursday, August 27, 2026 Celularity Inc. stock [NASDAQ: CELU] is trending up by 13.58%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
CELU is trading like a classic beaten-down biotech spec. On the daily chart, Celularity Inc. has climbed from around $0.64 to a recent close near $0.88, a steady grind higher over a few weeks. The move isn’t parabolic, but CELU is clearly attracting more trading volume and wider intraday ranges.
The intraday tape tells the real story. CELU opened around $0.92, ripped as high as $1.40 within minutes, then slid back under $1. That kind of move is pure momentum-trader territory. It shows both eager buyers and fast profit-taking in CELU, with liquidity good enough to support quick scalps but dangerous for anyone chasing.
Fundamentally, Celularity Inc. is still deep in the red. The latest report shows about $4.1M in quarterly revenue and roughly $26.6M over the trailing year, but operating losses are huge: EBITDA around -$22.6M for the quarter and net income about -$24.4M. CELU’s margins are extremely negative, and return on assets is deeply underwater.
More Breaking News
- Bloom Energy Stock Surges As AI Power Demand Explodes
- CIFR Stock Drops As Cipher Digital Misses Q2 Targets
- BRNX Stock Rockets On Low-Float Momentum And Debt Risk
- Bloom Energy Stock Surges On AI Power Demand And Big Beat
Balance sheet quality is a concern. Celularity Inc. carries negative equity of roughly -$38.1M and current liabilities far above current assets. For CELU traders, that means the chart can run, but the underlying business is still in survival mode.
Why Traders Are Watching CELU Price Action
CELU is on watch lists because the chart is starting to come alive while the fundamentals remain beaten down. That combination is exactly what short-term traders gravitate to. Celularity Inc. has moved from the mid-$0.60s to the high-$0.80s, with multiple days where CELU tested and rejected the $1 area. That round number is now a clear psychological battleground.
On the intraday chart, CELU’s spike from $0.92 to $1.40 in the first few minutes of trading shows what happens when momentum crowding hits a thin float name. Celularity Inc. attracted fast buyers, then just as fast, CELU rolled over as early traders locked in gains. That pattern—morning spike, midday fade, possible late-day bounce—is a classic setup pattern that day traders study daily.
Under the hood, Celularity Inc. is still trying to buy time. CELU’s operating cash flow was about -$5.1M for the latest quarter, but the company raised roughly $2M via preferred stock and used financing activities to increase cash by about $6.1M, ending with roughly $16.4M on hand. Traders read that as a short runway, not a disaster, which keeps CELU in play.
The current ratio around 0.2 and quick ratio near 0.1 tell a simple story: Celularity Inc. has limited cushion. For CELU, that usually translates to overhang from potential capital raises or restructuring. In trading terms, that’s fuel for future spikes on any whiff of positive data or funding news, and fuel for sharp dumps if dilution headlines hit. Until then, CELU’s chart is the main guide, with $0.70–$0.75 acting as recent support and $1 as the line in the sand overhead.
Conclusion
CELU is a textbook speculative biotech trade right now. The daily trend for Celularity Inc. has turned up in the short term, but the fundamentals are still heavily skewed toward losses and balance-sheet stress. That gap between a perky chart and fragile financials is exactly what short-term CELU traders try to exploit, not something to ignore.
Celularity Inc. is generating real revenue, yet gross profit is negative and operating expenses are heavy. CELU’s negative book value and thin liquidity tell you this isn’t a “safe” play; it’s a trading vehicle. That’s why experienced traders focus on levels, not stories. Support in the $0.70s and resistance near $1 give clear lines in the sand for CELU, while the wild intraday spike to $1.40 reminds everyone how fast these names can move.
For active traders studying CELU, the plan is simple: respect the volatility, track the dilution risk, and let price action lead. As Tim Sykes likes to say, “Discipline and risk management are more important than any hot stock tip.” As Tim Bohen, lead trainer with StocksToTrade says, “Success in trading is more about cutting losses quickly than finding winners.” Celularity Inc. is giving the market a live case study in that mindset. CELU can reward sharp, prepared traders—but only those who treat it as a trade, stick to their rules, and cut losses without hesitation.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.